Verma S, Bain SC, Buse JB, et al. - Researchers undertook this post hoc analysis of a randomized clinical trial, named as the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER), to determine if there exists a link of liraglutide with decreased first and recurrent total major adverse cardiovascular events (MACE) vs placebo in patients with type 2 diabetes and high risk of cardiovascular events. Randomization 1:1 of patients to receive liraglutide (up to 1.8 mg per day) or placebo, both with standard care, for 3.5 to 5.0 years, was done. They reported the occurrence of 1,605 MACE, including 1,302 first and 303 recurrent events, in 9,340 participants suffering from type 2 diabetes and carrying a high risk of cardiovascular events. Findings revealed decreased total MACE in relation to liraglutide treatment vs placebo among participants. In this high-risk patient population, an absolute advantage of liraglutide therapy regarding the overall burden of cardiovascular events was supported.